11/11/2025
📣 Big News for Women’s Health! 📣
Today, the FDA announced it will remove the highest-level “black box” warning from many menopausal hormone replacement therapies — marking a major shift in how these treatments are framed and understood. 
What this means:
👉🏼 Many HRT products approved for relief of menopausal symptoms like hot flashes, night sweats, and vaginal changes will no longer carry the “black box” warning about cardiovascular disease, breast cancer, and dementia — for certain formulations and under specific conditions. 
👉🏼 The FDA is working with drug manufacturers to update labeling to reflect current evidence about benefits and risks, to help healthcare providers and patients make more informed decisions. 
👉🏼 Important nuance: Some warnings remain — for example, systemic estrogen-alone products in women with a uterus still retain the boxed warning for endometrial cancer. 
👉🏼 Based on newer data: Starting HRT within 10 years of menopause onset (or before age 60) has shown benefits for symptom relief, bone health, cognition, and possibly cardiovascular outcomes — giving context to this change. 
Why this matters:
✨ For many women, the black box warning has been a major barrier—fueling fear, confusion, and avoidance of therapies that might help. This regulatory change invites renewed conversations between women and their healthcare providers about whether HRT could be right for them. 
📌 Important reminder:
This does not mean HRT is risk-free or that it’s the right choice for everyone. Each individual’s health history, timing of starting therapy, type of therapy, and goals must be discussed with a trusted clinician.
If you’re going through menopause or approaching it, this is an incredible time to talk about your symptoms, your risk/benefit situation, and whether HRT might be part of your care plan.
The team at VIA Women’s Health Collective would be honored to help you navigate that journey!
md whnp karah
